NextCell Pharma AB Total Liabilities

Latest as of August 2025: Skr10.34 Million SEK ≈ $1.11 Million USD

NextCell Pharma AB total liabilities. Based on the latest financial reports, NextCell Pharma AB (NXTCL) has total liabilities worth Skr10.34 Million SEK (≈ $1.11 Million USD) as of August 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check NextCell Pharma AB (NXTCL) liquid assets ratio to evaluate the company's liquid asset resilience ratio.

Total Liabilities of NextCell Pharma AB (2015–2025)

Total liabilities of NextCell Pharma AB from 2015 to 2025. This chart illustrates how NextCell Pharma AB's total liabilities have evolved over time, based on quarterly financial data.

NextCell Pharma AB Competitors by Total Liabilities

The table below lists competitors of NextCell Pharma AB ranked by their total liabilities.

Company	Country	Total Liabilities
H&T Group plc LSE:HAT	UK	GBX98.53 Million
Predilife PA:ALPRE	France	€7.12 Million
Datadot Technology Ltd AU:DDT	Australia	AU$610.61K
Osia Hyper Retail Limited NSE:OSIAHYPER	India	Rs-4.32 Billion
Autozi Internet Technology (Global) Ltd. Class A Ordinary Shares NASDAQ:AZI	USA	$43.59 Million
J-Star Holding Co., Ltd. Ordinary Shares NASDAQ:YMAT	USA	$13.93 Million
Pinnacle Minerals Ltd AU:PIM	Australia	AU$243.62K
Maple Peak Investments Inc V:MAP	Canada	CA$44.00K

Liability Composition Analysis (2015–2025)

This chart breaks down NextCell Pharma AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see NextCell Pharma AB total assets.

Liquidity & Leverage Metrics

NextCell Pharma AB Total Liabilities Ratios Explained

NextCell Pharma AB total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.

Metric	Value	Description
Current Ratio	10.02	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.16	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.13	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how NextCell Pharma AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for NextCell Pharma AB (2015–2025)

The table below shows the annual total liabilities of NextCell Pharma AB from 2015 to 2025.

Year	Total Liabilities	Change
2025-08-31	Skr10.34 Million ≈ $1.11 Million	-24.44%
2024-08-31	Skr13.69 Million ≈ $1.47 Million	+4.49%
2023-08-31	Skr13.10 Million ≈ $1.41 Million	+43.70%
2022-08-31	Skr9.12 Million ≈ $981.08K	+64.75%
2021-08-31	Skr5.53 Million ≈ $595.49K	+55.62%
2020-08-31	Skr3.56 Million ≈ $382.64K	-5.37%
2019-08-31	Skr3.76 Million ≈ $404.34K	+8.31%
2018-08-31	Skr3.47 Million ≈ $373.31K	+35.85%
2017-08-31	Skr2.55 Million ≈ $274.79K	-5.47%
2016-08-31	Skr2.70 Million ≈ $290.70K	+4.40%
2015-08-31	Skr2.59 Million ≈ $278.46K	--

About NextCell Pharma AB

ST:NXTCL Sweden Biotechnology

Market Cap

$3.43 Million

Skr31.91 Million SEK

Market Cap Rank

#29234 Global

#659 in Sweden

Share Price

Skr0.29

Change (1 day)

+13.02%

52-Week Range

Skr0.23 - Skr1.69

All Time High

Skr29.60